Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals

No abstract is available for this paper.

• Publication year

  2016

• Venue

  PharmacoEconomics (Auckland)

• Publication date

  2016-01-09

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1007/s40273-015-0373-9PMID 26748919
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C

  2016cited by this paper
• Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods

  2016cited by this paper
• Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

  2015cited by this paper
• A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service

  2015cited by this paper
• Cost‐effectiveness of sofosbuvir for the treatment of chronic hepatitis C‐infected patients

  2015cited by this paper
• Economic Evaluations with Agent-Based Modelling: An Introduction

  2015cited by this paper
• Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus

  2015cited by this paper
• Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.

  2015cited by this paper
• Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

  2015influential reference
• Cost-Effectiveness of Boceprevir Co-Administration versus Pegylated Interferon-α2b and Ribavirin Only for Patients with Hepatitis C Genotype 1 in Singapore

  2015cited by this paper
• The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection

  2015cited by this paper
• Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy

  2015cited by this paper
• Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

  2015cited by this paper
• The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

  2015cited by this paper
• Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States

  2015cited by this paper
• Are high drug prices for hematologic malignancies justified? A critical analysis

  2015cited by this paper
• Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

  2014cited by this paper
• Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010

  2014cited by this paper
• Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C

  2014cited by this paper
• Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations

  2014cited by this paper
• Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C

  2014cited by this paper
• The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions

  2014cited by this paper
• Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C

  2014cited by this paper
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  2014cited by this paper
• Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands

  2014cited by this paper
• Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients

  2014cited by this paper
• Cost‐effectiveness of sofosbuvir‐based triple therapy for untreated patients with genotype 1 chronic hepatitis C

  2014cited by this paper
• Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia.

  2014cited by this paper
• Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

  2014cited by this paper
• Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients

  2014cited by this paper
• Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia

  2014cited by this paper
• Therapy for hepatitis C--the costs of success.

  2014cited by this paper
• Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals

  2014cited by this paper
• The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients

  2014cited by this paper
• Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

  2013cited by this paper
• Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.

  2013cited by this paper
• Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients

  2013cited by this paper
• All‐oral, interferon‐free treatment for chronic hepatitis C: cost‐effectiveness analyses

  2013cited by this paper
• Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

  2013cited by this paper
• Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

  2013cited by this paper
• Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

  2013cited by this paper
• HCV treatment--no more room for interferonologists?

  2013cited by this paper
• Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States

  2013cited by this paper
• Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

  2013cited by this paper
• Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal

  2013cited by this paper
• Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection.

  2012cited by this paper
• Cost‐effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C

  2012cited by this paper
• New Protease Inhibitors for the Treatment of Chronic Hepatitis C

  2012cited by this paper
• Model Parameter Estimation and Uncertainty Analysis

  2012cited by this paper
• Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5

  2012cited by this paper
• Modeling Good Research Practices—Overview

  2012cited by this paper
• State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.

  2012cited by this paper
• Model Transparency and Validation

  2012cited by this paper
• State-Transition Modeling

  2012cited by this paper
• Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.

  2012cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Clinical practice. Chronic hepatitis C infection.

  2011influential reference
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.

  2011cited by this paper
• Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.

  2011cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

  2008cited by this paper
• Systematic assessment of decision models in Parkinson's disease.

  2004cited by this paper

• The association of direct-acting antiviral therapy with health care utilization and costs in patients with chronic hepatitis C virus infection: A systematic review of real-world studies in the United States.

  2025cites this paper
• Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?

  2024cites this paper
• Impact of Transmission Dynamics and Treatment Uptake, Frequency and Timing on the Cost-effectiveness of Directly Acting Antivirals for Hepatitis C Virus Infection

  2024influential citation
• Impact of direct‐acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings

  2023cites this paper
• Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients

  2023cites this paper
• Quercetin: A Functional Food-Flavonoid Incredibly Attenuates Emerging and Re-Emerging Viral Infections through Immunomodulatory Actions

  2023cites this paper
• An Oral English Evaluation Model Using Artificial Intelligence Method

  2022cites this paper
• Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis.

  2022cites this paper
• Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits

  2021cites this paper
• Value appropriation in hepatitis C

  2021cites this paper
• Taxonomy of Mathematical Modeling Studies for Hepatitis C Among Injection Drug Users

  2021cites this paper
• Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination

  2021cites this paper
• The direct-medical costs associated with interferon- based treatment for Hepatitis C in Vietnam [version 2; peer review: 2 approved]

  2021cites this paper
• Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report.

  2021cites this paper
• Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study

  2021cites this paper
• Flavonoid content of the Libyan Onosma Cyrenaicum: isolation, identification, electronic chemical reactivity, drug likeness, docking, and MD study

  2021cites this paper
• Opioid use disorder and HCV (hepatitis C virus)

  2021cites this paper
• Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses

  2020cites this paper
• Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review.

  2020cites this paper
• Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results

  2020cites this paper
• Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review

  2020cites this paper
• Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective

  2020cites this paper
• Management of Hepatitis C in Children and Adolescents.

  2020cites this paper
• The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam [version 1; peer review: 2 approved]

  2020cites this paper
• Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment

  2020cites this paper
• Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam

  2020cites this paper
• Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy: Analisi di costo-efficacia dei farmaci ad azione antivirale diretta nel trattamento dell’epatite cronica C nella popolazione carceraria italiana

  2020cites this paper
• Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy

  2020cites this paper
• A model of the economic benefits of global hepatitis C elimination: an investment case.

  2020cites this paper
• Long‐term clinical benefits of Sofosbuvir‐based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa

  2020cites this paper
• Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?

  2020cites this paper
• Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results

  2020cites this paper
• Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience

  2019cites this paper
• Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review

  2019cites this paper
• Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection

  2019cites this paper
• What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism

  2019influential citation
• No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis

  2019cites this paper
• Age‐dependent optimal policies for hepatitis C virus treatment

  2019cites this paper
• The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam.

  2019cites this paper
• Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis

  2019cites this paper
• Required Treatment Expenditures for Hepatitis C Virus Infection and Advantage in the Reduction of Hepatocellular Carcinoma Incidence: Analysis of Possible Options in an Endemic Area

  2019cites this paper
• An Agent-Based Model of Hepatitis C Virus Transmission Dynamics in India

  2019influential citation
• AN AGENT-BASED MODEL OF HEPATITIS C VIRUS TRANSMISSION DYNAMICS IN INDIA

  2019influential citation
• The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam

  2019cites this paper
• M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID

  2019cites this paper
• Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals.

  2018cites this paper
• Adverse drug reactions during hepatitis C treatment with direct‐acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system

  2018cites this paper
• Cost‐effective options for the prevention and management of gastrointestinal and liver disease in the Asia–Pacific region

  2018cites this paper
• Cost‐effectiveness analyses of anti‐hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan

  2018cites this paper
• Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses

  2018influential citation
• CHRONIC HEPATITIS C IS STILL A PROBLEM FOR THE PUBLIC HEALTH CARE SYSTEM IN BRAZIL.

  2018cites this paper
• Modelling the elimination of hepatitis C virus infection as a public health threat

  2018cites this paper
• Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis

  2018cites this paper
• Non-healthcare costs of hepatitis C: a systematic review

  2018cites this paper
• Feasibility of reaching world health organization targets for hepatitis C and the cost‐effectiveness of alternative strategies

  2018cites this paper
• Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

  2018cites this paper
• Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review

  2018cites this paper
• Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence

  2018cites this paper
• Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment

  2018cites this paper
• Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España

  2017cites this paper
• Systematic review: cost‐effectiveness of direct‐acting antivirals for treatment of hepatitis C genotypes 2‐6

  2017influential citation
• Cost‐effectiveness of elbasvir/grazoprevir use in treatment‐naive and treatment‐experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States

  2017cites this paper
• Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients

  2017cites this paper
• Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain.

  2017cites this paper
• The impact of hepatitis C virus outside the liver: Evidence from Asia

  2017cites this paper
• Direct‐Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost‐Saving

  2017cites this paper
• Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

  2017cites this paper
• Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C

  2017cites this paper
• Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease

  2017cites this paper
• Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?

  2017cites this paper
• Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India

  2017cites this paper
• Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview

  2017cites this paper
• A systematic review of health economic evaluation in adjuvant breast radiotherapy: Quality counted by numbers.

  2017cites this paper
• The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States

  2016cites this paper
• Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.

  2016cites this paper
• Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy

  2016influential citation
• Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States

  2016cites this paper
• Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets

  2016cites this paper
• Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 1; peer review: 1 approved, 1 approved with reservations]

  year unknowncites this paper